Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Begins "Open Format" Initative; Strikes Assay Pact with IDT

Premium

WaferGen Biosystems said this week that it has initiated a new "open format" strategy that will facilitate custom assay development for customers on its SmartChip real-time PCR system.

In addition, WaferGen said that it has established a relationship with Integrated DNA Technologies to provide that company's PrimeTime qPCR Primers for SYBR-based gene expression assays.

WaferGen's new assay-design program, called MyDesign, allows customers to dispense their own assays in a variety of configurations, thus enabling "easy and rapid design of new experiments," the company said.

After loading their custom content on MyDesign SmartChips, customers will be able to perform high-throughput qPCR gene expression and single nucleotide polymorphism genotyping projects more simply and cost-effectively, the company said.

"The MyDesign concept has greatly expanded our ability to utilize the SmartChip System in our laboratory," Jo Vandesompele, professor of functional genomics and applied bioinformatics at Ghent University, said in a statement.

"We were able to successfully conduct diverse experiments such as long non-coding RNA expression analysis, as well as perform genotyping and target enrichment for next-generation sequencing," Vandesompele added. "The ability to dispense assays on the spot and to test different configurations has significantly increased the speed of content selection and validation."

In conjunction with the MyDesign launch, WaferGen announced its partnership with IDT, which has developed more than 800,000 SYBR-based gene expression assays featuring PrimeTime qPCR primers and using a sophisticated design engine that eliminates cross reactivity and includes up-to-date SNP and intron/exon junction information.

The two companies will also collaboratively provide custom assay design services for formalin-fixed, paraffin-embedded samples to WaferGen customers.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.